Innovative dual-target drug may lead to new investigational approach for breast cancer patients

Innovative dual-target drug may lead to new investigational approach for breast cancer patients

Source: The Peter Doherty Institute for Infection and Immunity

Researchers, led by the University of Melbourne’s Professor Laura Mackay, a Laboratory Head and Immunology Theme Leader at the Peter Doherty Institute of Infection and Immunity (Doherty Institute), in collaboration with Pfizer, have discovered new insights into possible future treatments for breast cancer.

Researchers, led by the University of Melbourne’s Professor Laura Mackay, a Laboratory Head and Immunology Theme Leader at the Peter Doherty Institute of Infection and Immunity (Doherty Institute), in collaboration with Pfizer, have discovered new in… [2816 chars]

Read more